Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,599.13 82.86 0.57%
TOPIX 1,176.93 3.56 0.30%
HANG SENG 22,760.24 64.23 0.28%

StockCall Study on Merck & Co., Pfizer, Johnson & Johnson, and AbbVie



    StockCall Study on Merck & Co., Pfizer, Johnson & Johnson, and AbbVie

PR Newswire

LONDON, March 12, 2013

LONDON, March 12, 2013 /PRNewswire/ --

On Monday, drug stocks ended mostly higher as the Dow Jones posted yet another
record high finish. Major pharmaceutical companies such as Merck & Co. Inc.
(NYSE: MRK), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), and
AbbVie Inc. (NYSE: ABBV) have been facing increasing completion from generic
drugs following the expiration of patents on several blockbuster drugs. Drug
companies are also evaluating the impact of President Obama's Affordable Care
Act (ACA) on their bottom-line. StockCall free coverage on MRK, PFE, JNJ, and
ABBV is available upon registration at

http://www.stockcall.com/register

Shares of Merck & Co. Inc. rose sharply in yesterday's trading session. The
stock closed 1.61% higher at $43.66 after touching an intra-day high of
$43.67. The drug maker's gains on Monday came on substantial volume, which
suggests that market sentiment has turned bullish on the stock. This is
confirmed by the stock's MACD chart. The MACD is currently trading above the
signal line and the zero-line. Merck's shares are currently facing resistance
at around $44. Year-to-date, its shares have gained more than 6.60%,
underperforming the broad market. Download the free technical research on MRK
by signing up at

http://www.StockCall.com/MRK031213.pdf

Shares of Pfizer Inc. posted modest gains in Monday's trading session. The
stock closed 0.21% higher at $28.25. Pfizer's shares are currently trading
close to their 52-week high of $28.38. The stock has had an excellent run this
year, gaining more than 12%, compared to a gain of over 9% for the S&P 500.
The stock recently broke through $27.50 resistance level, which is a bullish
signal. The bullish trend is further confirmed by recent volume activity. The
stock's MACD is also trading above the signal line. Register now and get
access to the free analysis on PFE at

http://www.StockCall.com/PFE031213.pdf

Shares of Johnson & Johnson edged higher in its most recent trading session;
however, the gains were limited. The stock closed 0.32% higher at $78.44 after
touching a 52-week high of $78.52 on Monday. Johnson & Johnson's shares have
gained more than 1% in the last three sessions. The drug maker's shares have
seen a series of highs since the start of this year, which is a strong bullish
signal. The upbeat trend is further confirmed by the stock's MACD chart. Sign
up and read the complimentary report on JNJ at

http://www.StockCall.com/JNJ031213.pdf

Shares of AbbVie Inc. gained nearly 1% on Monday. The stock closed 0.88%
higher at $37.67. AbbVie's shares have outperformed the broad market this
year, gaining more than 10%. The stock is currently facing stiff resistance at
$38.50. It has support at around $37. The company's shares are currently
trading above their 50-day and 200-day moving averages. The free report on
ABBV can be downloaded by signing up now at

http://www.StockCall.com/ABBV031213.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

Contact: Contact Person:William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement